Abionyx Pharma SA Working Capital to Net Assets Ratio
Abionyx Pharma SA working capital to net assets ratio. Abionyx Pharma SA (ABNX) has a Working Capital to Net Assets ratio of 28.9% as of June 2025. Working capital of €1.57 Million (current assets of €5.45 Million minus current liabilities of €3.88 Million) is measured against net assets of €5.41 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Abionyx Pharma SA (ABNX) tangible equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Abionyx Pharma SA (2013–2024)
Working capital to net assets ratio of Abionyx Pharma SA from 2013 to 2024. This chart shows how Abionyx Pharma SA's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of June 2025, the ratio stands at 28.9%, reflecting working capital of €1.57 Million against net assets of €5.41 Million EUR. See defensive interval ratio of Abionyx Pharma SA to measure how many days the company can operate on defensive assets alone.
Abionyx Pharma SA Working Capital to Net Assets Ratio by Year (2013–2024)
Abionyx Pharma SA working capital to net assets ratio by year from 2013 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Abionyx Pharma SA from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see ABNX asset base.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 29.0% | €2.15 Million | €7.42 Million | €5.86 Million | €3.71 Million | ▼ -8.4 pp |
| 2023 | 37.4% | €2.96 Million | €7.92 Million | €6.89 Million | €3.92 Million | ▲ +2.8 pp |
| 2022 | 34.6% | €2.48 Million | €7.17 Million | €7.57 Million | €5.09 Million | ▼ -24.1 pp |
| 2021 | 58.7% | €6.26 Million | €10.68 Million | €13.01 Million | €6.75 Million | ▼ -38.4 pp |
| 2020 | 97.1% | €6.43 Million | €6.63 Million | €10.03 Million | €3.60 Million | ▼ -2.8 pp |
| 2019 | 99.9% | €6.66 Million | €6.67 Million | €10.12 Million | €3.47 Million | ▼ -11.5 pp |
| 2018 | 111.4% | €4.27 Million | €3.84 Million | €12.78 Million | €8.51 Million | ▼ -53.3 pp |
| 2017 | 164.6% | €14.63 Million | €8.89 Million | €17.87 Million | €3.24 Million | ▲ +13.8 pp |
| 2016 | 150.8% | €22.03 Million | €14.61 Million | €28.72 Million | €6.69 Million | ▲ +30.7 pp |
| 2015 | 120.1% | €39.87 Million | €33.20 Million | €45.66 Million | €5.79 Million | ▼ -50404.9 pp |
| 2014 | 50525.0% | €6.06 Million | €12.00K | €10.76 Million | €4.70 Million | ▲ +50351.7 pp |
| 2013 | 173.3% | €10.68 Million | €6.16 Million | €13.76 Million | €3.08 Million | — |